CCWM
LXRX icon

Cassaday & Co Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4K Hold
1,000
– – ﹤0.01% 1016
2026
Q1 		$1.56K Buy
+1,000
New +$1.45K ﹤0.01% 1094

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Cassaday & Co Wealth Management's LXRX Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 1,000 shares worth $2.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1016.

Cassaday & Co Wealth Management first reported a position in LXRX in Q1 2026 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Cassaday & Co Wealth Management held 1,000 shares of Lexicon Pharmaceuticals worth $2.4K as of Q2 2026.
  • Cassaday & Co Wealth Management left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1016 holding.
  • Cassaday & Co Wealth Management first reported a position in Lexicon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.